
To assess the association between combination, dose and use of current guideline‐recommended target doses (TD) of renin–angiotensin system inhibitors (RASi), angiotensin receptor–neprilysin inhibitors (ARNi) and β‐blockers, and outcomes in a large and unselected contemporary cohort of patients with heart failure (HF) and reduced ejection fraction. Heart failure with reduced ejection fraction patients using higher doses of RASi or ARNi and β‐blockers had lower risk of cardiovascular death or HF hospitalization. In addition, the use of two drug classes at 50%–99% of TD dose was associated with a lower risk than one drug class at 100% of TD.
Like
Save
Share